Merck granted FDA approval to expand Bravecto label for tick species in dogs

Merck has received FDA approval to expand the label for its Bravecto product, which treats additional tick species in dogs, potentially increasing sales in the animal health segment. While this is a positive development for Merck's veterinary portfolio, the overall financial impact is expected to be limited as it represents a niche market and may already be anticipated by investors. Macro headwinds in the pharmaceutical sector, such as regulatory scrutiny and competition, could offset any gains.